Ying Sun1,2, Zhanjun Jia1, Guangrui Yang1, Yutaka Kakizoe1, Mi Liu1,3, Kevin T Yang1,3, Ying Liu1, Baoxue Yang2, Tianxin Yang1,3. 1. Department of Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, UT, United States. 2. Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, China. 3. Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China.
Abstract
BACKGROUND & AIMS: Microsomal prostaglandin E synthase-2 (mPGES-2) deletion does not influence in vivo PGE2 production and the function of this enzyme remains elusive. The present study was undertaken to investigate the role of mPGES-2 in streptozotocin (STZ)-induced type-1 diabetes and organ injuries. METHODS: mPGES-2 wild type (WT) and knockout (KO) mice were treated by a single intraperitoneal injection of STZ at the dose of 120 mg/kg to induce type-1 diabetes. Subsequently, glycemic status and organ injuries were evaluated. RESULTS: Following 4 days of STZ administration, mPGES-2 KO mice exhibited severe lethality in contrast to the normal phenotype observed in WT control mice. In a separate experiment, the analysis was performed at day 3 of the STZ treatment in order to avoid lethality. Blood glucose levels were similar between STZ-treated KO and WT mice. However, the livers of KO mice were yellowish with severe global hepatic steatosis, in parallel with markedly elevated liver enzymes and remarkable stomach expansion. However, the morphology of the other organs was largely normal. The STZ-treated KO mice displayed extensive hepatocyte apoptosis compared with WT mice in parallel with markedly enhanced inflammation and oxidative stress. More interestingly, a liver-specific 50% upregulation of GLUT2 was found in the KO mice accompanied with a markedly enhanced STZ accumulation and this induction of GLUT2 was likely to be associated with the insulin/SREBP-1c pathway. Primary cultured hepatocytes of KO mice exhibited an increased sensitivity to STZ-induced injury and higher cellular STZ content, which was markedly blunted by the selective GLUT2 inhibitor phloretin. CONCLUSIONS: mPGES-2 deletion enhanced STZ-induced liver toxicity possibly via GLUT2-mediated STZ uptake, independently of diabetes mellitus.
BACKGROUND & AIMS:Microsomal prostaglandin E synthase-2 (mPGES-2) deletion does not influence in vivo PGE2 production and the function of this enzyme remains elusive. The present study was undertaken to investigate the role of mPGES-2 in streptozotocin (STZ)-induced type-1 diabetes and organ injuries. METHODS:mPGES-2 wild type (WT) and knockout (KO) mice were treated by a single intraperitoneal injection of STZ at the dose of 120 mg/kg to induce type-1 diabetes. Subsequently, glycemic status and organ injuries were evaluated. RESULTS: Following 4 days of STZ administration, mPGES-2 KO mice exhibited severe lethality in contrast to the normal phenotype observed in WT control mice. In a separate experiment, the analysis was performed at day 3 of the STZ treatment in order to avoid lethality. Blood glucose levels were similar between STZ-treated KO and WT mice. However, the livers of KO mice were yellowish with severe global hepatic steatosis, in parallel with markedly elevated liver enzymes and remarkable stomach expansion. However, the morphology of the other organs was largely normal. The STZ-treated KO mice displayed extensive hepatocyte apoptosis compared with WT mice in parallel with markedly enhanced inflammation and oxidative stress. More interestingly, a liver-specific 50% upregulation of GLUT2 was found in the KO mice accompanied with a markedly enhanced STZ accumulation and this induction of GLUT2 was likely to be associated with the insulin/SREBP-1c pathway. Primary cultured hepatocytes of KO mice exhibited an increased sensitivity to STZ-induced injury and higher cellular STZ content, which was markedly blunted by the selective GLUT2 inhibitor phloretin. CONCLUSIONS:mPGES-2 deletion enhanced STZ-induced liver toxicity possibly via GLUT2-mediated STZ uptake, independently of diabetes mellitus.
Authors: M Masutani; H Suzuki; N Kamada; M Watanabe; O Ueda; T Nozaki; K Jishage; T Watanabe; T Sugimoto; H Nakagama; T Ochiya; T Sugimura Journal: Proc Natl Acad Sci U S A Date: 1999-03-02 Impact factor: 11.205
Authors: D L Eizirik; D G Pipeleers; Z Ling; N Welsh; C Hellerström; A Andersson Journal: Proc Natl Acad Sci U S A Date: 1994-09-27 Impact factor: 11.205
Authors: A R Kraynak; R D Storer; R D Jensen; M W Kloss; K A Soper; J H Clair; J G DeLuca; W W Nichols; R S Eydelloth Journal: Toxicol Appl Pharmacol Date: 1995-12 Impact factor: 4.219
Authors: Lauren M Cagen; Xiong Deng; Henry G Wilcox; Edwards A Park; Rajendra Raghow; Marshall B Elam Journal: Biochem J Date: 2005-01-01 Impact factor: 3.857